Tag - ZNTL

SVB Leerink initiated coverage of Zentalis Pharmaceuticals (NASDAQ:ZNTL) with an “outperform” rating and $45 price target. The stock closed at $31.76 on April 27. Zentalis’ lead compound is an oral selective estrogen...